The launch of CipherX's Microdot Tattoo in London this month is best understood as a commercialisation move, not a scientific breakthrough. The underlying technology — dissolving microneedles that carry tattoo ink into the upper layers of skin — has existed in research form since at least 2022. What CipherX has done is take that concept and build a consumer product around it, targeting the substantial share of people who want a tattoo but avoid one because of needle aversion.
The company, a London-based biotech startup co-founded by Ferdinand Kohle and Karl-Anton Harms, held a launch event in Shoreditch on 23 July 2026 and has since opened the product to the public through a series of pop-up events. Dezeen reported that CipherX had completed approximately 500 applications before the commercial launch.
The mechanics are straightforward. Each single-use patch is covered in hundreds of microneedles made from carbon-based tattoo ink combined with a biodegradable biopolymer. A handheld applicator presses the patch into the upper skin layers. The needles dissolve over 15 minutes, leaving pigment behind. Yanko Design reported that the tattoo appears pale immediately after the patch is removed and darkens over the following 48 hours. Aftercare requires petroleum jelly and avoiding prolonged water exposure during that period.
CipherX describes the process as pain-free on the basis that the microneedles do not penetrate as deeply as traditional tattoo needles. The company's own guidance, however, notes the possibility of temporary redness or mild irritation, according to Designboom. Whether independent clinical or dermatological safety assessments have been undertaken is not publicly known, nor is CipherX's regulatory approval status in the UK or elsewhere.
The current product is tightly constrained. Designs are limited to carbon black ink and must fit within a 15-millimetre circular canvas. Available motifs include hearts, stars, and a reproduction of Van Gogh's Chair, according to Yanko Design and the Daily Mail. Individual designs range from 3 to 11 millimetres, Dezeen reported. Each tattoo costs £50 and is accessible only at CipherX pop-up events, not in tattoo studios or retail outlets.
Those constraints reflect both the technology's current limits and a deliberate distribution strategy. Home application and broader retail availability are on the company's roadmap but are not yet offered, according to Designboom. The pop-up model allows CipherX to control the application environment while accumulating real-world data — a sensible approach for a product whose long-term colour fidelity and permanence, relative to traditional methods, remains unverified.
The academic foundation for this class of product predates CipherX by several years. Researchers at the Georgia Institute of Technology, led by Professor Mark Prausnitz, published work on ink-laden dissolving microneedle patches in the journal iScience in 2022. The Independent reported at the time that the researchers framed their work primarily around veterinary and medical applications, with cosmetic use cited as a future possibility. Wales Online noted that the microneedles in that research were smaller than a grain of sand.
CipherX's move is therefore the first attempt to translate that research into a commercial cosmetic product. Whether the £50 price point and the pop-up distribution model can sustain a viable business — or whether the product can scale to larger canvases and multiple colours — remains to be seen. For now, the company has established a working proof of concept in the market, which is a meaningful step even if the product's boundaries are narrow.
Comments (0)